Journal
ANTIVIRAL THERAPY
Volume 27, Issue 1, Pages -Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/13596535221082773
Keywords
-
Categories
Ask authors/readers for more resources
Remdesivir, the first antiviral for COVID-19, has been widely used to treat 10 million patients worldwide. Its development path started more than a decade earlier in the search for a cure for hepatitis C virus. This journey represents an important example of pandemic preparedness, supported by John C. Martin's sustained commitment.
If a planned path reaches a dead-end, one can simply stop. Or one can turn around, walk back to the last intersection and take another path, or one can consider taking few paths in parallel. The last scenario is reflective of the journey of remdesivir, the first antiviral for the treatment of COVID-19, that was approved by FDA less than 10 months after the isolation of SARS-CoV-2, the virus responsible for the COVID-19 pandemic. As of January 2022, 10 million COVID-19 patients have been treated with remdesivir worldwide, but the journey of this molecule started more than a decade earlier with the search for a cure of hepatitis C virus. The development path of remdesivir before the emergence of COVID-19 represents a valuable example of a preemptive pandemic preparedness, but the pursuit of this path would not have been possible without sustaining support of John C. Martin, whom we will sorely miss for his piercing vision, uncompromising leadership, and genuine compassion for patients suffering around the world.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available